Sutro Biopharma, Inc. (STRO)
NASDAQ: STRO · Real-Time Price · USD
1.955
-0.015 (-0.76%)
Jan 23, 2025, 12:18 PM EST - Market open
Sutro Biopharma Revenue
Sutro Biopharma had revenue of $8.52M in the quarter ending September 30, 2024, a decrease of -49.66%. This brings the company's revenue in the last twelve months to $160.96M, up 230.90% year-over-year. In the year 2023, Sutro Biopharma had annual revenue of $153.73M with 126.84% growth.
Revenue (ttm)
$160.96M
Revenue Growth
+230.90%
P/S Ratio
0.87
Revenue / Employee
$532,964
Employees
302
Market Cap
161.21M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 87.70B |
Merck & Co. | 63.17B |
AbbVie | 55.53B |
AstraZeneca | 51.21B |
Novartis AG | 49.94B |
Thermo Fisher Scientific | 42.37B |
Abbott Laboratories | 41.95B |
STRO News
- 15 days ago - Sutro Biopharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 20 days ago - Sutro Biopharma: I Don't Buy That Their Pipeline Is Worthless - Seeking Alpha
- 2 months ago - Sutro Biopharma Reports Third Quarter 2024 Financial Results and Business Highlights - GlobeNewsWire
- 2 months ago - Sutro Biopharma Demonstrates Meaningful ADC Innovation with Five Presentations at the 15th Annual World ADC Conference - GlobeNewsWire
- 2 months ago - Sutro Biopharma Announces Initiation of the Registration-enabling REFRαME-P1 Trial with Luvelta for Pediatric Patients with CBF/GLIS AML - GlobeNewsWire
- 3 months ago - Sutro Biopharma Highlights Next-Generation ADC Innovation and Near-term Pipeline at Research Forum - GlobeNewsWire
- 4 months ago - Sutro Biopharma's Competitive ADCs Position It For Future Growth In Oncology - Seeking Alpha
- 4 months ago - Sutro Biopharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire